Cancer therapy is rapidly evolving from a one-size-fits-all paradigm toward highly personalized approaches. Traditional chemotherapies and radiotherapies, while broadly applied, often yield suboptimal outcomes due to tumor heterogeneity and are limited by significant toxicities. In contrast, precision oncology tailors prevention, diagnosis, and treatment to the individual patient’s genetic and molecular profile. Key advancements underscore this shift: molecularly targeted drugs (e.g., trastuzumab for HER2-positive breast cancer, EGFR and ALK inhibitors for lung cancer) have improved efficacy and reduced toxicity compared to conventional therapy. Pharmacokinetic (PK) and pharmacodynamic (PD) considerations are central to personalizing treatment, explaining variability in drug exposure and response among patients and guiding dose optimization. Modern strategies like therapeutic drug monitoring and model-informed precision dosing seek to maintain drug levels in the therapeutic range, improving outcomes. Immunotherapies, including checkpoint inhibitors and CAR-T cells, have transformed oncology, though patient selection via biomarkers (such as PD-L1 expression or tumor mutational burden) is critical to identify likely responders. Innovative drug delivery systems, notably nanomedicine, address PK challenges by enhancing tumor-specific drug accumulation and enabling novel therapeutics. Furthermore, rational combination regimens (informed by PK/PD and tumor biology) are being designed to achieve synergistic efficacy and overcome resistance. Key barriers include the high cost of biomarker testing, insufficient laboratory infrastructure, and inconsistent reimbursement policies. Operational inefficiencies such as long turnaround times or lack of clinician awareness further limit the use of precision diagnostics. Regulatory processes also remain complex, particularly around the co-development of targeted drugs and companion diagnostics, and the evidentiary requirements for rare subgroups. Addressing these barriers will require harmonized policies, investment in infrastructure, and educational initiatives to ensure that the promise of personalized medicine becomes accessible to all patients. Ensuring that advances are implemented responsibly—guided by pharmacological insights, supported by real-world evidence, and evaluated within ethical and economic frameworks—will be critical to realizing the full potential of personalized cancer medicine.

This review aims to provide a comprehensive overview of the botany, phytochemical composition, and dermatological effects of Cydonia oblonga (CO), with a particular focus on its therapeutic mechanisms across various skin conditions. Among the different parts of the plant, the fruit and peel are especially rich in bioactive compounds, primarily polyphenols such as phenolic acids, anthocyanins, and flavonoids, which are known for their potent antioxidant activity. These constituents contribute significantly to the fruit and peel’s health-promoting properties. To date, multiple extracts derived from various CO parts have been studied in both in vitro and in vivo models. Reported dermatological effects include antioxidant, antimicrobial, anti-inflammatory, anti-allergic, UV-protective, moisturizing, and anti-aging effects, as well as beneficial outcomes in conditions such as wound healing, erythema, and hyperpigmentation. As a result, formulations containing CO-derived compounds have been developed for use in both diseased and healthy skin care. However, only a limited number of these effects have been validated in human clinical studies. Given the promising results from preclinical research, future directions should prioritize in vivo investigations in human subjects to determine optimal concentrations and delivery systems for targeting specific skin disorders.

Vital pulp therapy aims to preserve pulp vitality by stimulating reparative processes. However, conventional approaches often result in incomplete tissue regeneration. Extracellular vesicles (EVs) have emerged as promising cell-free therapeutic agents because of their ability to regulate angiogenesis, odontogenesis, and immune responses through the transfer of bioactive molecules. Despite their significant regenerative potential, the clinical application of EVs remains limited by rapid clearance, insufficient local retention, and uncontrolled release following administration. To address these challenges, various extracellular matrix (ECM)-based and ECM-bioinspired scaffolds have been developed as delivery platforms. These scaffolds can provide structural support and enable controlled, localized release of EVs. This narrative review critically evaluates the current evidence regarding scaffold systems as EV delivery platforms for dental pulp regeneration, comparing their biological performance, methodological quality, and translational potential. Across the available studies, scaffold-assisted EV delivery consistently enhanced angiogenesis, odontogenic differentiation, mineralization, and immunomodulation; however, the evidence remains preclinical and is characterized by substantial heterogeneity regarding EV source, isolation and characterization methods, scaffold composition, experimental models, and outcome assessment. Current findings support the feasibility of scaffold-assisted EV delivery for regenerative endodontics, but important challenges remain, including standardization of EV production and characterization, scalable manufacturing, regulatory approval, and demonstration of long-term safety and functional pulp–dentin complex regeneration. Further well-designed translational and clinical studies will be essential before routine clinical implementation can be considered.

This paper aims to collect all the necessary information and conclusions which deal with the anti-inflammatory drugs within the scope of teeth bleaching, and which are rooted in scientific research. It is a well-known fact that the teeth whiteners / bleachers are at the same time a very aggressive agents, which opened up the question of the safety of their application. The most frequently applied bleaching agents are the hydrogen-peroxide (H₂O₂) and carbim peroxide (CH₆N₂O₃), therefore this paper will be based on the research which included these two agents. The first studies were directed towards investigating the outcome / impact on the enamel, i.e. if there is direct surface damage of the enamel layer after the use of such agents. However, bearing in mind that the clinical practice has shown that in a number of cases there arises the sensitivity of teeth in the form of painful sensation after the bleaching treatment, some researches were directed towards the estimation of the permeability of the enamel and dentin for the bleaching agent, and later the effect on the pulp tissue. Along with the existing proof about the irritability of these agents to the pulp tissue, the modern research have the idea of looking into the effects of the anti-inflamatory drugs as the accompanying and prevention therapy of any of the irreversible damage of the pulp. On one hand the application of these drugs can reduce the sensitivity and painfulness of the teeth, which makes the intervention pleasant for the patient, but on the other hand the intervention becomes completely justifiable from the aspect of safety and the basic principle primum non nocere. The anti-inflammatory drugs which will be the topic of this study are H hydrocortisone, acetaminophen, ipobruphen and etodolac. Taking into consideration the vasoconstrictive and anti-oxidative effect, the anti-inflammatory effect of the carvedilol will be looked into, which belongs to the group of beta blockers. Based on available informations it can be noticed that the most efficient anti-inflammatory effect in teeth whitening is achived by hydrocortisone.

Alzheimer’s disease (AD) is a complex neurodegenerative condition marked by a gradual decline in cognitive abilities, a reduction in acetylcholine (ACh) levels, and the accumulation of β-amyloid (Aβ) plaques. In a healthy brain, approximately 80% of ACh is broken down by acetylcholinesterase (AChE). Meanwhile, butyrylcholinesterase (BChE) serves a supportive function, gaining significance as AChE activity diminishes during the progression of Alzheimer’s disease. Modern therapeutic approaches focus on creating dual inhibitors of AChE and BChE that also aim to diminish Aβ-amyloidogenesis through interactions with the peripheral anionic site (PAS). This study combined fragment-based molecular design (CReM), AI-assisted retrosynthetic feasibility assessment, and in silico evaluation (docking, molecular dynamics, and ADMET profiling) to identify novel Donepezil derivatives as potential dual AChE/BChE inhibitors. A series of 10,000 derivatives were developed through computational methods and carefully assessed based on stringent drug-likeness, synthetic accessibility, and medicinal chemistry standards. This was succeeded by comprehensive ADMET profiling. Nine candidates were identified with predicted CNS pharmacokinetics, adequate toxicological profiles and reduced cytochrome P450 liabilities. Molecular docking yielded improved predicted binding affinities relative to Donepezil. Several derivatives, particularly D4 and D5, showed dual-site binding poses spanning both the catalytic gorge and the PAS. MD simulations indicated the stability of these poses over 100 ns. These computational results suggest that the proposed derivatives may preserve or improve upon Donepezil’s pharmacokinetic profile while offering potentially balanced AChE/BChE inhibition and anti-amyloidogenic activity, pending experimental validation.